Announcement PDF RNS Number : 0463S OptiBiotix Health PLC 06 July 2020 OptiBiotix Health plc ("OptiBiotix" or the "Company") Extension of terms for WellBiome® OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has extended the terms of its original distribution agreement with CTC Holding BV ("CTC") as announced on 1 October 2018 and subsequent amendment as announced on 28 January 2020. The agreement extends the product range from the distribution of SlimBiome®, SlimBiome® Medical and GoFigure® to include WellBiome®. The territories remain unchanged with distribution rights in the Philippines, Vietnam, Indonesia, Colombia, the Dominican Republic and Guatemala. The agreement is for an initial period of 18 months from January 2020 with renewal of terms linked to sales targets. WellBiome® is a proprietary blend of prebiotic functional fibres, functional dietary fibres and mineral optimised for health and wellbeing by promoting the diversity of the gut microbiome. WellBiome® was launched at the end of June 2020 (RNS: 29 June 2020) in response to commercial partners expressing strong interest in a microbiome modulating ingredient that would expand the commercial opportunity beyond slimming and provide a science based solution to the Health & Wellness industry, a market estimated to be worth US$4.2 trillion in 2019. The agreement with CTC is the first example of a partner transitioning from an expression of interest to a contractual agreement. Dr. Lars Wiemann, Chief Scientific Officer at CTC, commented: "We see WellBiome® as an evolution of SlimBiome®, that extends the main target from weight loss & hunger control towards improving your gut health and thus your immune health as well as your general health. Recent scientific research has shown that boosting your immune system by improving your gut health is a proven concept. Therefore, WellBiome® perfectly fits into CTC's global strategy for health supporting ingredients and we are really happy we can offer this innovative product to our clients now." Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce the extension of terms for CTC. This agreement recognises CTC's success in building sales of SlimBiome® and extends terms to enhance further sales growth, supported by minimum sales targets. This is a first commercial step in bringing our new functional ingredient WellBiome® to global markets and building brand awareness." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. For further information, please contact: OptiBiotix Health plc Stephen O'Hara, Chief Executive www.optibiotix.com Contact via Walbrook below Cairn Financial Advisers LLP (NOMAD) Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880 finnCap (Broker) Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) Tel: 020 7220 0500 Walbrook PR Ltd Anna Dunphy Mob: 07876 741 001 About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END MSCEAKXDEFNEEFA